

RECEIVED  
CENTRAL FAX CENTER  
AUG 18 2006

USSH: 10/520,698  
Attorney Docket: I-2002.010 US  
Preliminary Amendment and Response to Restriction Requirement

**Amendments to the Claims:**

Please replace the pending claims with the following claims:

1.-14. (cancelled)

15. (new) A method of preparing an immunogenic composition comprising
- i) combining a heterologous hydrophobic polypeptide to the N-terminus and/or the C-terminus of a core polypeptide thereby forming a fusion protein; and
  - ii) mixing said fusion protein with a saponin adjuvant in a free form, thereby forming said immunogenic composition;

wherein said heterologous hydrophobic polypeptide has a hydrophobicity of 0.6 or more as determined by dividing (a) by (b),

wherein (a) is the number of hydrophobic data points of said heterologous hydrophobic polypeptide as determined using the Kyte-Doolittle hydrophobicity analysis using a window of 5 amino acids, and (b) is the total number of amino acids of said heterologous hydrophobic polypeptide; and

wherein said core polypeptide has a protective epitope.

16. (new) The method according to claim 15, wherein the core polypeptide is a component of a protein of an organism of the phylum Apicomplexa.

USSN: 10/520,698

Attorney Docket: I-2002.010 US

Preliminary Amendment and Response to Restriction Requirement

17. (new) The method according to claim 16, characterized in that the core polypeptide is a component of a protein of an organism of the Piroplasmida or of the class Coccidia.
18. (new) The method according to claim 17, wherein the core polypeptide is a component of a protein of an organism of the genera Eimeria or Babesia.
19. (new) The method according to claim 15, wherein the heterologous hydrophobic peptide is from an N-terminal hydrophobic sequence.
20. (new) The method according to claim 15, wherein the heterologous hydrophobic peptide is from an internal hydrophobic sequence.
21. (new) The method according to claim 15, wherein the heterologous hydrophobic peptide is from a C-terminal hydrophobic sequence.
22. (new) The method according to claim 21, wherein the C-terminal hydrophobic sequence is from decay accelerating factor (DAF).
23. (new) The method according to claim 15, wherein the saponin adjuvant is Quillaja saponin.

USSN: 10/520,698

Attorney Docket: I-2002.010 US

Preliminary Amendment and Response to Restriction Requirement

24. (new) A method of preparing a vaccine comprising admixing the immunogenic composition made according to the method of claim 15 with a pharmaceutically acceptable carrier.

25. (new) The method of claim 24, wherein at least one additional immunoactive component is combined with said vaccine.

26. (new) The method of claim 24, wherein said vaccine is freeze-dried.

27. (new) An immunogenic composition obtained by the method according to claim 15.

28. (new) A vaccine obtained by the method according to claim 24.